🎉 M&A multiples are live!
Check it out!

Oscotec Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oscotec and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Oscotec Overview

About Oscotec

Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases.


Founded

1998

HQ

South Korea
Employees

n/a

Website

oscotec.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$812M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Oscotec Financials

Oscotec has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Oscotec achieved revenue of $23.2M and an EBITDA of $1.3M.

Oscotec expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Oscotec valuation multiples based on analyst estimates

Oscotec P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $3.4M $23.2M XXX XXX XXX
Gross Profit $2.1M $2.0M XXX XXX XXX
Gross Margin 61% 9% XXX XXX XXX
EBITDA -$20.5M $1.3M XXX XXX XXX
EBITDA Margin -606% 6% XXX XXX XXX
Net Profit -$16.6M -$16.5M XXX XXX XXX
Net Margin -493% -71% XXX XXX XXX
Net Debt $3.0M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Oscotec Stock Performance

As of April 15, 2025, Oscotec's stock price is KRW 33500 (or $23).

Oscotec has current market cap of KRW 1.28T (or $873M), and EV of KRW 1.19T (or $812M).

See Oscotec trading valuation data

Oscotec Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$812M $873M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Oscotec Valuation Multiples

As of April 15, 2025, Oscotec has market cap of $873M and EV of $812M.

Oscotec's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Oscotec's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Oscotec and 10K+ public comps

Oscotec Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $812M XXX XXX XXX
EV/Revenue 35.1x XXX XXX XXX
EV/EBITDA 625.5x XXX XXX XXX
P/E 1461.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -44.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oscotec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Oscotec Valuation Multiples

Oscotec's NTM/LTM revenue growth is n/a

Oscotec's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Oscotec's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Oscotec's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Oscotec and other 10K+ public comps

Oscotec Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 587% XXX XXX XXX XXX
EBITDA Margin 6% XXX XXX XXX XXX
EBITDA Growth -106% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 8% XXX XXX XXX XXX
G&A Expenses to Revenue 5% XXX XXX XXX XXX
R&D Expenses to Revenue 63% XXX XXX XXX XXX
Opex to Revenue 101% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Oscotec Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Oscotec M&A and Investment Activity

Oscotec acquired  XXX companies to date.

Last acquisition by Oscotec was  XXXXXXXX, XXXXX XXXXX XXXXXX . Oscotec acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Oscotec

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Oscotec

When was Oscotec founded? Oscotec was founded in 1998.
Where is Oscotec headquartered? Oscotec is headquartered in South Korea.
Who is the CEO of Oscotec? Oscotec's CEO is Mr. Jeong-Geun Kim.
Is Oscotec publicy listed? Yes, Oscotec is a public company listed on KRX.
What is the stock symbol of Oscotec? Oscotec trades under 039200 ticker.
When did Oscotec go public? Oscotec went public in 2007.
Who are competitors of Oscotec? Similar companies to Oscotec include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Oscotec? Oscotec's current market cap is $873M
What is the current revenue growth of Oscotec? Oscotec revenue growth between 2023 and 2024 was 587%.
Is Oscotec profitable? Yes, Oscotec is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.